Non-participants (n = 208) | MiDEAR participants BL (n = 60) | MiDEAR participant follow-up (N = 51) | NDB (n = 8481) | |
---|---|---|---|---|
Age (mean (SD)) years | 61.2 (14.8) | 50.1 (13.1)* | 49.1 (12.3)* | 62.6 (14.0) |
Female (n (%)) | 150 (72.1) | 47 (78.3)* | 40 (78.4)* | 6369 (75.1) |
Disease duration (mean (SD)) years | 10.0 (10.1) | 10.5 (9.1)* | 10.5 (9.7)* | 13.3 (10.3) |
DAS28 (mean (SD)) baseline | 2.7 (1.1) | 2.6 (1.0)* | 2.6 (1.0)* | 2.8 (1.0) |
DAS28 (mean (SD)) follow-up | n.a. | n.app. | 2.5 (0.8) | n.a. |
HAQ (mean (SD)) (Paper-based for MIDEAR participants) | 1.21 (0.71) | 0.78 (0.59)* | 0.69 (0.50)* | 0.88 (0.69) |
HAQ (mean (SD)) follow-up (Paper-based for MIDEAR participants) | n.a. | n.app. | 0.69 (0.50) | n.a. |
Number of co-morbidities (median (IQR)) | 2 (1.0–3.0) | 2 (1.0–3.8)* | 2 (0–3.0) * | 2 (1.0–4.0) |
Education: University entrance diploma (n (%)) | 59 (28.4) | 30 (50.0)* | 28 (54.9)* | 1120 (24.4) |
Medication | ||||
NSAIDs (n (%)) | 85 (40.9) | 28 (46.7) | 24 (47.1) | 2782 (48.6) |
Glucocorticoids (n (%)) | 121 (58.2) | 30 (50.0) | 26 (51.0) | 2717 (47.5) |
csDMARDs alone (n (%)) | 115 (55.3) | 36 (60.0) | 30 (58.8) | 3485 (61.1) |
Biological DMARD either alone or in combination with csDMARD (n (%)) | 67 (32.2) | 20 (33.3) | 17 (33.3) | 1576 (27.6) |